Sexually Transmitted Diseases (STDs) are diseases that spread from person-to-person through sexual contact. Early identification or diagnosis of STDs can help stop further transmission. Laboratory tests can identify the cause and detect co-infections through blood tests, urine samples, swab tests, lumbar puncture, and fluids samples. Testing for a disease in someone who doesn't have symptoms is called screening. The screening can be done for a variety of infections like HIV, hepatitis B, chlamydia, syphilis, gonorrhea, and hepatitis C. Cervical cancer is often caused by certain strains of HPV. Treatment of STDs can be done by antibiotics and antiviral drugs which prevents the further spread of disease.
Market Dynamics
The increasing prevalence of STDs, government fundings for the treatment and management of STDs is expected to drive the global diagnostic testing of STDs market growth. For instance, on February 2, 2023, Mylab Discovery Solutions Pvt. Ltd., an India-based biotechnology company, launched rapid test kits for sexually transmitted diseases including human immunodeficiency virus (HIV), Hepatitis C virus (HCV), and syphilis. Among these tests, HIV 1/2 Ab, and HCV Ab are rapid tests for the detection of antibodies specific to HIV-1, HIV-2, and HCV respectively, while the syphilis antibody test detects antibodies (IgG, IgA, and IgM) to aid in the diagnosis of syphilis.
Key features of the study:
- This report provides an in-depth analysis of the global diagnostic testing of STDs market and provides market size (US$ Bn) and Compound Annual Growth Rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global diagnostic testing of STDs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- The key companies covered as a part of this study include Vela Diagnostics USA Inc., Roche Holdings AG, Alere, Inc., Becton Dickinson & Company, bioMerieux, Danaher Corporation (Beckman Coulter), Hologic, Inc., binx health, Chembio Diagnostics, Pinpoint Science Inc., and bioLytical Laboratories.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type upgrade, market expansion, and marketing tactics
- The global diagnostic testing of STDs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global diagnostic testing of STDs market
Detailed Segmentation:
- Global Diagnostic Testing of STDs Market, By Test Type:
- Chlamydia
- Gonorrhea
- Syphilis
- HIV
- HPV+pap smear
- HSV
- Chancroid
- Global Diagnostic Testing of STDs Market, By Region:
- North America
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- U.K.
- Germany
- France
- Spain
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- North Africa
- Central Africa
- South Africa
- Company Profiles
- Vela Diagnostics USA Inc.
- Roche Holdings AG
- Alere, Inc.
- Becton Dickinson & Company
- bioMerieux
- Danaher Corporation (Beckman Coulter)
- Hologic, Inc.
- binx health
- Chembio Diagnostics
- Pinpoint Science Inc.
- bioLytical Laboratories
